高级检索
当前位置: 首页 > 详情页

Identification of G2 and S Phase-Expressed-1 as a Potential Biomarker in Patients with Prostate Cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Department of Urology, Peking UnionMedical College Hospital, Peking UnionMedical College, Chinese Academy ofMedical Sciences, Beijing 100730, People’sRepublic of China [2]Department ofUrology, Beijing Friendship Hospital,Capital Medical University, Beijing100050, People’s Republic of China
出处:
ISSN:

关键词: prostate cancer GTSE1 bioinformatics analysis prognosis

摘要:
Background: This study aimed to predict and explore the possible clinical value and mechanism of genetic markers in prostate cancer (PCa) using a bioinformatics analysis method. Materials and Methods: The RNA-seq data were downloaded from The Cancer Genome Atlas (TCGA) database to identify the differentially expressed genes (DEGs). The hub genes were screened by building protein-protein interaction (PPI) subnetworks with four topological analysis methods. The overall survival analysis of hub genes was conducted using Kaplan-Meier curves. Furthermore, the bioinformatics results were confirmed in 102 PCa samples collected in our hospital. Gene Set Enrichment Analysis (GSEA) was performed to provide information about the molecular mechanisms underlying PCa. Results: Among 13 hub genes, the high expression of GTSE1 or KIF18B was associated with worse overall survival according to the TCGA samples. Immunoreactive scores for GTSE1 staining were significantly higher in PCa tissues than in paracancerous tissues (P< 0.01). The overall survival time of patients with high GTSE1 expression was shorter than that of patients with low GTSE1 expression (P=0.015). GSEA demonstrated that high GTSE1 expression was mainly enriched in the cell cycle (P< 0.001), DNA replication (P< 0.001), mismatch repair (P< 0.001), and p53 signaling pathway (P< 0.001). Conclusion: GTSE1 expression was significantly high in PCa and associated with poor prognosis. GTSE1 may serve as a potential biomarker and therapeutic target in PCa patients.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2018]版:
Q3 ONCOLOGY
最新[2023]版:
Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2018版] 出版当年五年平均[2014-2018] 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者单位: [1]Department of Urology, Peking UnionMedical College Hospital, Peking UnionMedical College, Chinese Academy ofMedical Sciences, Beijing 100730, People’sRepublic of China
通讯作者:
通讯机构: [1]Department of Urology, Peking UnionMedical College Hospital, Peking UnionMedical College, Chinese Academy ofMedical Sciences, Beijing 100730, People’sRepublic of China [2]Department ofUrology, Beijing Friendship Hospital,Capital Medical University, Beijing100050, People’s Republic of China [*1]Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Dongcheng District, Beijing 100730, People’s Republic of China [*2]Department of Urology, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong-An Road, Xicheng District, Beijing 100050, People’s Republic of China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:817 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)